• Save
Lung Cancer Stages, Treatments and Targeted Therapies - David Barbie, MD
Upcoming SlideShare
Loading in...5
×
 

Like this? Share it with your network

Share

Lung Cancer Stages, Treatments and Targeted Therapies - David Barbie, MD

on

  • 2,809 views

Audio and slides for this presentation are available on YouTube: http://youtu.be/rt_O7m2eTYA ...

Audio and slides for this presentation are available on YouTube: http://youtu.be/rt_O7m2eTYA

David Barbie, MD, of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, discusses the stages of lung cancer, how the disease is treated, and new targeted therapies for patients. This presentation was originally given at Dana-Farber's "Living with Lung Cancer" forum on Nov. 2, 2013.

Statistics

Views

Total Views
2,809
Views on SlideShare
2,763
Embed Views
46

Actions

Likes
2
Downloads
1
Comments
0

3 Embeds 46

https://twitter.com 39
http://www.linkedin.com 6
https://www.linkedin.com 1

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Lung Cancer Stages, Treatments and Targeted Therapies - David Barbie, MD Presentation Transcript

  • 1. Lung Cancer: Stages, Treatments and Targeted Therapies David Barbie, M.D. Lowe Center for Thoracic Oncology Dana-Farber Cancer Institute Assistant Professor of Medicine, Harvard Medical School November 2, 2013
  • 2. Lung Cancer Incidence and Mortality in U.S. KRAS Mutation ~30% ~50% ~90%
  • 3. Lung Cancer Stages and Treatments
  • 4. Lung Cancer Stages and Treatments Stage 1: Localized
  • 5. Lung Cancer Stages and Treatments Stage 1: Localized Stage 2: Larger (> 5 cm) or spread to local lymph nodes Surgery, +/-chemotherapy
  • 6. Lung Cancer Stages and Treatments Stage 1: Localized Stage 2: Larger (> 5 cm) or spread to local lymph nodes Surgery, +/-chemotherapy Stage 3: Locally advanced Chemotherapy and radiation, +/- surgery
  • 7. Lung Cancer Stages and Treatments Stage 1: Localized Stage 2: Larger (> 5 cm) or spread to local lymph nodes Brain Surgery, +/-chemotherapy Stage 3: Locally advanced Chemotherapy and radiation, +/- surgery Bone Stage 4: Advanced/metastatic Chemotherapy +/- palliative radiation Liver Adrenals
  • 8. Oncogenes are the Jammed Accelerators of Cancer Cells
  • 9. BCR-ABL - BCR-ABL + Shtivelman et al. Nature 1985;315:550 Daley et al. Science 1990;247:824 Buchdunger et al. Cancer Res 1996;56:100 Deininger et al. Blood 1997;90:3691 Druker, BJ. Nat Med 2009;15:1149
  • 10. Lynch et al. NEJM 2004;350:2129 Paez et al. Science 2004;304:1497
  • 11. Mok et al. NEJM 2009;361:947
  • 12. Better than chemotherapy, but tumors become resistant after 10-12 months Mok et al. NEJM 2009;361:947
  • 13. Genomic complexity of lung cancer CML Lung Adenocarcinoma http://www.path.cam.ac.uk http://www.utoronto.ca/cancyto
  • 14. Lung Cancer Then and Now Many different oncogenes can get jammed No known genotype 1984 - 2003 No known genotype 2004 Erlotinib X X 2009 Crizotinib 2012 Courtesy of Stephanie Cardarella, MD, DFCI Thoracic Oncology
  • 15. Chemotherapy Targets the Engine, Targeted Therapy the Accelerator EGFR inhibitor ALK inhibitor BRAF inhibitor Carboplatin + Alimta or Taxol
  • 16. DFCI Patient with NSCLC and BRAF mutation treated with Dabrafenib August 10, 2012 September 19, 2012 Courtesy of Stephanie Cardarella, MD, DFCI Thoracic Oncology
  • 17. MSKCC Patient with NSCLC and BRAF mutation treated with Dabrafenib February 2012 June 2012 Courtesy of Gregory Riely, MD, Memorial Sloan-Kettering Cancer Center
  • 18. KRAS is Difficult To Target Directly KRAS inhibitor – failed clinical trials
  • 19. Alternatives to Targeting KRAS 1. Block known downstream pathways (between pedal and engine) Also failing in clinical trials
  • 20. Alternatives to Targeting KRAS 1. Block known downstream pathways (between pedal and engine) XX Also failing in clinical trials X X
  • 21. Alternatives to Targeting KRAS 2. Use genomics to identify currently unknown pathways needed for survival (that keep car from crashing) TBK1
  • 22. CYT387 Impairs Viability of Lung cancer Cells A549 Lung Cancer Cells DMSO CYT387 (5mM)
  • 23. Activity of CYT387 in Kras-driven Murine Lung Cancer Murine KRAS-Driven Lung Cancer CYT387 100mg/kg/d H Baseline H Week 16 Kwok Wong Travis Cohoon
  • 24. Activity of CYT387 in Kras-driven Murine Lung Cancer H E pA ST T3 A B Uee n ad t t r 2m 5 µ C 2m 5 µ D Tor an a t el e xe o 2m 5 µ E 2m 5 µ F C an Yl e To 2m 5 µ 2m 5 µ
  • 25. Alternatives to Targeting KRAS Blocking multiple unique pathways
  • 26. Alternatives to Targeting KRAS Blocking multiple unique pathways X X X X
  • 27. Activity of CYT387 in Kras-driven Murine Lung Cancer KrasLSL-G12D/WT;p53flox/flox model with established tumor burden *p<0.01 **p<0.0001 CYT387: 100 mg/kg/daily by oral gavage Selumetinib: 25 mg/kg/twice daily by oral gavage Kwok Wong Travis Cohoon
  • 28. Activity of CYT387 in Kras-driven Murine Lung Cancer KrasLSL-G12D/WT;p53flox/flox model with established tumor burden *p<0.01 **p<0.0001 Treatment well tolerated other than initial gavage trauma CYT387: 100 mg/kg/daily by oral gavage Selumetinib: 25 mg/kg/twice daily by oral gavage Kwok Wong Travis Cohoon
  • 29. Immunotherapy – “Immune Checkpoint Blockade”
  • 30. Immunotherapy – “Immune Checkpoint Blockade”
  • 31. Immunotherapy – “Immune Checkpoint Blockade” PD-L1 PD-L1 PD-L1
  • 32. Immunotherapy – “Immune Checkpoint Blockade” T cell T cell PD1 PD1 PD-L1 PD-L1 PD-L1 PD1 T cell
  • 33. Immunotherapy – “Immune Checkpoint Blockade” T cell X T cell PD1 X PD1 PD-L1 PD-L1 PD-L1 T cell X PD1
  • 34. Immunotherapy – “Immune Checkpoint Blockade” T cell PD-L1 targeted drugs T cell X PD1 X PD1 PD-L1 PD-L1 PD-L1 T cell X PD1
  • 35. Immunotherapy – “Immune Checkpoint Blockade” T cell T cell PD1 PD1 PD1 T cell
  • 36. Immunotherapy – “Immune Checkpoint Blockade” T cell T cell PD1 PD1 PD1 T cell
  • 37. Summary • Lung cancer can be treated with a combination of surgery, radiation, and chemotherapy depending on the stage
  • 38. Summary • Lung cancer can be treated with a combination of surgery, radiation, and chemotherapy depending on the stage • We continue to develop new ways to target lung cancer more directly, with increasing success
  • 39. Summary • Lung cancer can be treated with a combination of surgery, radiation, and chemotherapy depending on the stage • We continue to develop new ways to target lung cancer more directly, with increasing success • With combinations of these new targeted therapies the future is very bright